Renaissance Technologies LLC Acquires 30,900 Shares of HilleVax, Inc. (NASDAQ:HLVX)

Renaissance Technologies LLC raised its holdings in HilleVax, Inc. (NASDAQ:HLVX) by 119.8% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 56,700 shares of the company’s stock after purchasing an additional 30,900 shares during the period. Renaissance Technologies LLC owned approximately 0.11% of HilleVax worth $820,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Dimensional Fund Advisors LP raised its position in shares of HilleVax by 31.7% in the second quarter. Dimensional Fund Advisors LP now owns 152,602 shares of the company’s stock valued at $2,204,000 after buying an additional 36,690 shares in the last quarter. TD Asset Management Inc lifted its position in shares of HilleVax by 53.9% during the 2nd quarter. TD Asset Management Inc now owns 54,236 shares of the company’s stock valued at $784,000 after acquiring an additional 19,000 shares during the period. Rhumbline Advisers grew its holdings in shares of HilleVax by 27.0% during the 2nd quarter. Rhumbline Advisers now owns 42,658 shares of the company’s stock worth $617,000 after purchasing an additional 9,073 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of HilleVax by 35.1% in the second quarter. Bank of New York Mellon Corp now owns 93,865 shares of the company’s stock worth $1,357,000 after purchasing an additional 24,410 shares during the period. Finally, Tidal Investments LLC acquired a new position in HilleVax in the first quarter valued at about $207,000. Institutional investors own 86.42% of the company’s stock.

HilleVax Stock Performance

Shares of HLVX opened at $1.80 on Tuesday. HilleVax, Inc. has a 52 week low of $1.55 and a 52 week high of $20.22. The stock has a market capitalization of $89.50 million, a price-to-earnings ratio of -0.55 and a beta of 0.80. The stock has a fifty day moving average of $1.79 and a 200-day moving average of $8.40.

HilleVax (NASDAQ:HLVX) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.10). As a group, equities analysts forecast that HilleVax, Inc. will post -2.47 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Guggenheim cut shares of HilleVax from a “buy” rating to a “neutral” rating in a research report on Monday, July 8th. Leerink Partners downgraded HilleVax from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $28.00 to $2.00 in a report on Tuesday, July 9th. Leerink Partnrs cut HilleVax from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 9th. HC Wainwright reaffirmed a “neutral” rating and issued a $2.00 price objective on shares of HilleVax in a research note on Monday, August 12th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating and set a $5.00 target price (down previously from $24.00) on shares of HilleVax in a research note on Monday, July 8th. Six equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $9.20.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.